تأثير علاج هرمون النمو على الطول لدى الأطفال المصابين بالكساح الناقص الفوسفات المرتبط بالكروموسوم X

Laurent MR, Harvengt P, Mortier GR, Böckenhauer D. X-linked hypophosphatemia. GeneReviews®[Internet]. 2023 Dec 14. Available from: https://www.ncbi.nlm.nih.gov/books/NBK83985/

André J, Zhukouskaya VV, Lambert AS, Salles JP, Mignot B, Bardet C, et al. Growth hormone treatment improves final height in children with X-linked hypophosphatemia. Orphanet Journal of Rare Diseases. 2022;17(1):1-8.

https://doi.org/10.1186/s13023-022-02590-5 PMid:36544157 PMCid:PMC9768884

Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nature Reviews Nephrology. 2019; 15(7):435-55.

https://doi.org/10.1038/s41581-019-0152-5 PMid:31068690 PMCid:PMC7136170

Cannalire G, Pilloni S, Esposito S, Biasucci G, Di Franco A, Street ME. Alkaline phosphatase in clinical practice in childhood: Focus on rickets. Frontiers in Endocrinology. 2023; 14:1111445. https://doi.org/10.3389/fendo.2023.1111445 PMid: 36817604 PMCid:PMC9931734

Rothenbuhler A, Esterle L, Gueorguieva I, Salles JP, Mignot B, Colle M, et al. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR). Growth Hormone & IGF Research. 2017;36:11-5. https://doi.org/10.1016/j.ghir.2017.08.001 PMid: 28822957

Chande S, Bergwitz C. Role of phosphate sensing in bone and mineral metabolism. Nature Reviews Endocrinology. 2018; 14(11):637-55. https://doi.org/10.1038/s41574-018-0076-3 PMid:30218014 PMCid:PMC8607960

Cagnoli M. Spontaneous growth and effect of early therapy with calcitriol and phosphate in X-linked hypophosphatemic rickets. Pediatr Endocrinol Rev. 2017; 17:119-22. https://doi.org/10.17458/per.vol15.2017.crb.spontaneousgrowtheffect

Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity Orphanet Journal of Rare Diseases. 2019;14:1-25. https://doi.org/10.1186/s13023-019-1014-8 PMid: 30808384 PMCid:PMC6390548

Baroncelli GI, Mora S. X-Linked hypophosphatemic rickets: Multisystemic disorder in children requiring multidisciplinary management. Frontiers in Endocrinology. 2021;12: 688309

https://doi.org/10.3389/fendo.2021.688309 PMid: 34421819 PMCid:PMC8378329

Trombetti A, Al-Daghri N, Brandi ML, Cannata-Andía JB, Cavalier E, Chandran M, et al. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nature Reviews Endocrinology. 2022; 18 (6):366-84. https://doi.org/10.1038/s41574-022-00662-x PMid:35484227

Rothenbuhler A, Schnabel D, Högler W, Linglart A. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). Metabolism. 2020;103:153892. https://doi.org/10.1016/j.metabol.2019.03.009 PMid: 30928313

Laurent MR, De Schepper J, Godefroid N, Levtchenko E, Vande Walle J. Consensus recommendations for the diagnosis and management of X-linked hypophosphatemia in Belgium. Frontiers in endocrinology. 2021 Mar 19;12:641543. https://doi.org/10.3389/fendo.2021.641543 PMid: 33815294 PMCid: PMC8018577

Živičnjak M, Schnabel D, Billing H, Staude H, Filler G, Querfeld U, et al. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatric Nephrology. 2011; 26:223-31.

https://doi.org/10.1007/s00467-010-1705-9 PMid: 21120538

Yakar S. Insulin-like growth factors: Actions 1 on the skeleton. J Mol Endocrinol 2018; 17‑0298. https://doi.org/10.1530/JME-17-0298

Živičnjak M, Schnabel D, Staude H, Even G, Marx M, Beetz R, et al. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab. 2011;96(12):E2097-105. https://doi.org/10.1210/jc.2011-0399 PMid:21994957

Seikaly MG, Brown R, Baum M. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics. 1997; 100(5):879-84. https://doi.org/10.1542/peds.100.5.879 PMid:9346990

Haffner D, Nissel R, Wuhl E, Mehls O. Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics. 2004;113(6):e593-6.

https://doi.org/10.1542/peds.113.6.e593 PMid:15173542

Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G. Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr.2001;138(2):236-43. https://doi.org/10.1067/mpd.2001.108955 PMid: 11174622

Carpenter TO, Whyte MP, Imel EA, Boot AM, Högler W, Linglart A, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018; 378: 1987-98. https://doi.org/10.1056/NEJMoa1714641 PMid: 29791829

Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. The Lancet. 2019;393(10189):2416-27. https://doi.org/10.1016/S0140-6736(19)30654-3 PMid:31104833

Ertl DA, Le Lorier J, Gleiss A, Trabado S, Bensignor C, Audrain C, et al. Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone. Orphanet Journal of Rare Diseases. 2022;17(1):1-2. https://doi.org/10.1186/s13023-022-02562-9 PMid: 36371259 PMCid: PMC9652849

Smith S, Remmington T. Recombinant growth hormone therapy for X-linked hypophosphatemia in children. Cochrane Database Syst Rev. 2021; 10(10).https://doi.org/10.1002/14651858.CD004447.pub3 PMid: 34618915 PMCid:PMC8496964